These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 10443700)
1. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. Mitsiades N; Poulaki V; Mastorakos G; Tseleni-Balafouta ST; Kotoula V; Koutras DA; Tsokos M J Clin Endocrinol Metab; 1999 Aug; 84(8):2924-32. PubMed ID: 10443700 [TBL] [Abstract][Full Text] [Related]
2. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619 [TBL] [Abstract][Full Text] [Related]
3. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988 [TBL] [Abstract][Full Text] [Related]
4. Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Mitsiades N; Poulaki V; Tseleni-Balafouta S; Chrousos GP; Koutras DA Thyroid; 2000 Jul; 10(7):527-32. PubMed ID: 10958304 [TBL] [Abstract][Full Text] [Related]
5. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320 [TBL] [Abstract][Full Text] [Related]
6. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Ni X; Hazarika P; Zhang C; Talpur R; Duvic M Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580 [TBL] [Abstract][Full Text] [Related]
7. [The role of Fas/FasL system in the regulation of tumor-immune system interactions in papillary thyroid carcinoma in children and adolescents]. Portianko AS; Cherstvoĭ ED Arkh Patol; 2003; 65(4):18-21. PubMed ID: 14518188 [TBL] [Abstract][Full Text] [Related]
8. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Kase S; Osaki M; Adachi H; Kaibara N; Ito H Int J Oncol; 2002 Feb; 20(2):291-7. PubMed ID: 11788891 [TBL] [Abstract][Full Text] [Related]
9. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741 [TBL] [Abstract][Full Text] [Related]
10. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844 [TBL] [Abstract][Full Text] [Related]
11. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649 [TBL] [Abstract][Full Text] [Related]
12. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638 [TBL] [Abstract][Full Text] [Related]
14. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174 [TBL] [Abstract][Full Text] [Related]
15. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Shukuwa T; Katayama I; Koji T Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912 [TBL] [Abstract][Full Text] [Related]
16. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571 [TBL] [Abstract][Full Text] [Related]
17. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620 [TBL] [Abstract][Full Text] [Related]
19. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989 [TBL] [Abstract][Full Text] [Related]
20. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. Koyama S; Koike N; Adachi S J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]